Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort.
Fiche publication
Date publication
décembre 2022
Journal
Journal of the American Academy of Dermatology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALAC Sophie, Dr GRANEL-BROCARD Florence
Tous les auteurs :
Rousset P, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Brunet-Possenti F, De Quatrebarbes J, Grob JJ, Saiag P, Maubec E, Stoebner PE, Granel-Brocard F, Arnault JP, Allayous C, Oriano B, Lebbe C, Montaudié H
Lien Pubmed
Résumé
Clinical outcomes of advanced melanoma of unknown primary (MUP) in the era of novel therapies have been scarcely studied.
Mots clés
advanced melanoma, adverse events, chemotherapy, immunotherapy, melanoma of known primary, melanoma of unknown primary, survival, systemic therapy, targeted therapy
Référence
J Am Acad Dermatol. 2022 12 19;: